首页> 美国卫生研究院文献>Clinical Orthopaedics and Related Research >Allograft-Prosthetic Composite in the Proximal Tibia After Bone Tumor Resection
【2h】

Allograft-Prosthetic Composite in the Proximal Tibia After Bone Tumor Resection

机译:骨肿瘤切除术后近端胫骨同种异体修复复合材料

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We consider an allograft-prosthesis composite in the proximal tibia one of the better reconstructive options in this site because it combines the mechanical stability of a prosthesis with the biologic reconstruction of the extensor mechanism. We retrospectively reviewed 62 patients who had proximal tibia reconstructions with allograft-prosthesis composites to ascertain the complications and functional outcomes. By combining an allograft with a prosthesis, placing cement in the graft, and press-fitting the prosthesis in the tibial diaphysis, we obtained satisfactory Musculoskeletal Tumor Society scores in 90.4% of patients, with a 5-year survival rate (73.4%) comparable to that of reconstruction with a modular prosthesis. However, we observed high infection rates (24.2%) and rotation of the medial gastrocnemius seemed not to reduce this complication. For this reason, we do not recommend using this reconstructive technique in patients who will receive postoperative chemotherapy or in patients in whom a previous reconstructive method failed. We believe the ideal candidate is the young patient with a benign aggressive or malignant low-grade tumor who has not undergone previous surgery.>Level of Evidence: Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
机译:我们认为胫骨近端的同种异体移植物复合物是该部位更好的重建选择之一,因为它结合了假体的机械稳定性和伸肌机制的生物学重建。我们回顾性分析了62例胫骨近端重建同种异体假体复合材料的患者,以确定并发症和功能结局。通过将同种异体移植物与假体相结合,将水泥放入移植物中,然后将假体压入胫骨干physi端,我们在90.4%的患者中获得了令人满意的肌肉骨骼肿瘤学会评分,其5年生存率(73.4%)可比模块化假体的重建。但是,我们观察到较高的感染率(24.2%),内侧腓肠肌的旋转似乎并没有减少这种并发症。因此,我们不建议在接受术后化疗的患者或先前的重建方法失败的患者中使用这种重建技术。我们认为,理想的候选人是尚未接受过手术的年轻,良性侵袭性或恶性低度肿瘤患者。>证据级别: IV级,治疗研究。有关证据水平的完整说明,请参见《作者指南》。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号